enGene Therapeutics Inc. (ENGN)

NASDAQ

$1.96

$+0.05

(+2.62%)

After-Hours

enGene Therapeutics Inc. (ENGN) Live Price Chart

Last updated: ⁦2026-09-21 23:30:01⁩. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.

Summary

enGene Therapeutics Inc. (ENGN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.96, with a market capitalization of $128.00M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.40 to $12.25. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$128.00M
Open	$1.92
Day's High	$52.84
Day's Low	$1.40
Previous Close	$1.91
Volume	418.65K
Average Volume	828.38K
P/E Ratio	--
52-Week High	$12.25
52-Week Low	$1.40
Dividend Yield	--
Earnings Date	--

enGene Therapeutics Inc. (ENGN) After-Hours Stock Price

enGene Therapeutics Inc. (ENGN) is trading at $1.93 in after-hours trading as of 2026-09-21 21:10:00, up 1.05% ($0.02) from the regular-session close of $1.91.

After-hours trading shows how investors are pricing ENGN after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.

enGene Therapeutics Inc. (ENGN) 7-Day Stock Price Change

Over the past seven days, enGene Therapeutics Inc. (ENGN) moved from $1.77 to $1.96, representing a gain of 10.96% ($0.19).

The stock traded between $1.76 and $1.96 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.

The average daily volume was 559.06 thousand shares, down versus the previous seven-day period, indicating lower trading activity.

ENGN 52-Week Price Position

Position in Range: 5.2%

52W Low$1.40

52W High$12.25

ENGN is currently trading at $1.96, placing it 5.2% of the way from its 52-week low of $1.40 to its 52-week high of $12.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is enGene Therapeutics Inc. (ENGN)?

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

enGene Therapeutics Inc. Information

Industry	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees	82
Exchange	NASDAQ
Company Website	https://www.engene.com

How to Buy enGene Therapeutics Inc. (ENGN) Stock on MEXC

Eligible investors can buy real shares of enGene Therapeutics Inc. (ENGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for ENGN and Place Your Order

Open the RealStocks trading page and search for ENGN. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is enGene Therapeutics Inc. (ENGN) stock price today?

enGene Therapeutics Inc. (ENGN) is currently trading at $ 1.96, up 2.83% ($0.05) from the previous close of $ 1.91. Intraday prices update in real time during regular trading hours.

2.Is ENGN stock going up or down today?

As of 2026-09-21 21:10:00, ENGN is trading at $ 1.96, up 2.83% ($0.05) from its previous close of $ 1.91. The stock has traded between $ 1.40 and $ 52.84 during today’s regular session. Past price movements do not guarantee future results.

3.What is ENGN pre-market price?

As of 2026-09-21 21:10:00, ENGN is trading at $ 1.88 in pre-market trading, down 1.57% ($0.03) from the previous close of $ 1.91. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is ENGN after-hours price?

As of 2026-09-21 21:10:00, ENGN is trading at $ 1.93 in after-hours trading, up 1.05% ($0.02) from the regular-session close of $ 1.91. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is ENGN stock trading now?

ENGN trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does ENGN sit relative to its 52-week high and low?

Over the past 52 weeks, ENGN has traded between a low of $ 1.40 and a high of $ 12.25. At $ 1.96, the stock is positioned 5.2% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is enGene Therapeutics Inc. in?

enGene Therapeutics Inc. (ENGN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is enGene Therapeutics Inc.'s market capitalization and where is it listed?

enGene Therapeutics Inc. is listed on the NASDAQ exchange with a market capitalization of $ 128.00M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is ENGN valued in terms of P/E ratio and EPS?

ENGN trades at a P/E ratio of --, based on trailing-twelve-month EPS of $ -1.95. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does enGene Therapeutics Inc. pay a dividend?

enGene Therapeutics Inc. pays an indicated annual cash dividend of $ 0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.